BackSuven gets US patent for potential drug to treat major depressive disorder
With this approval, Suven said its drug discovery portfolio has expanded into several new therapeutic areas
Premium
Hyderabad: Suven Life Sciences Ltd on Wednesday said it has secured a product patent in the US corresponding to a new chemical entity for the treatment of disorders associated with neurodegenerative diseases.
With this approval, Suven said its drug discovery portfolio has expanded into several new therapeutic areas such as major depressive disorder, obesity and pain through neuronal nicotinic receptor modulators.
The company said the patent was valid through 2030.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorders.
“Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," the company said.
Suven has a total of 18 granted patents from the US.
Shares of Suven rose 4.73% to ₹ 89.65 on BSE at 12.02pm, while the exchange’s benchmark Sensex fell 0.03% to 24,849.90 points.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
